BioDelivery Sciences International, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioDelivery Sciences International, Inc.
The higher dose of Amgen's Lumakras combined with Vectibix has demonstrated significant superiority in progression-free survival over investigator's choice of therapy in KRAS G12C-mutated metastatic colorectal cancer but the discussant at the combo's ESMO presentation wants to see overall survival data before getting too excited.
The Danish giant’s GLP-1 agonist blockbuster is effective against diabetes, obesity and cardiovascular disease. Now kidney disease can be added to the list after a Phase III trial was halted for efficacy.
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Arius Pharmaceuticals
- Arius Two Inc
- Bioral Nutrient Delivery LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.